Wall Street Analysts See a 44.47% Upside in Omnicell ( OMCL ) : Can the Stock Really Move This High?
The mean of analysts' price targets for Omnicell (OMCL) points to a 44.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Omnicell ( OMCL ) Beats Q2 Earnings and Revenue Estimates
Omnicell (OMCL) delivered earnings and revenue surprises of +45.16% and +4.99%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Can Sustained Product Demand Drive HIMS Stock Before Q2 Earnings?
Hims & Hers benefits from strong product demand and subscriber growth ahead of second-quarter 2025 earnings, fueled by weight loss and specialty care uptake.
OMCL vs. DOCS: Which Stock Is the Better Value Option?
Investors with an interest in Medical Info Systems stocks have likely encountered both Omnicell ( OMCL Quick QuoteOMCL - ) and Doximity ( DOCS Quick QuoteDOCS - ) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
Inspire Medical Systems ( INSP ) Expected to Beat Earnings Estimates: Should You Buy?
Inspire (INSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Omnicell ( OMCL ) to Report a Decline in Earnings: What to Look Out for
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
American Well ( AMWL ) Soars 5.0%: Is Further Upside Left in the Stock?
American Well (AMWL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Can OPRX's Patient Engagement Tools Win Amid Fierce Competition?
OptimizeRx bets on EHR-linked messaging and geo-targeting to stand out, but scaling in a crowded digital health field remains key.
3 Medical Info Systems Stocks to Buy Amid AI Boom and Tariff Risk
AI momentum and rising demand for digital care put Zacks Medical Info Systems industry stocks like VEEV, TXG and IMDX in focus despite new tariff headwinds.
Capsa Healthcare Unveils Industry's First Consolidated Services Pharmacy Platform
CANAL WINCHESTER, Ohio, July 08, 2025 ( GLOBE NEWSWIRE ) -- Capsa Healthcare, a leader in healthcare automation and medication management, today announced the launch of its Consolidated Services Pharmacy Platform ( CSPP ) - the industry's first integrated solution that unifies central fill ...
Do Options Traders Know Something About Omnicell Stock We Don't?
Investors need to pay close attention to OMCL stock based on the movements in the options market lately.
Is it Apt to Retain Omnicell Stock in Your Portfolio Now?
OMCL stays on investors' radar due to its strong 2025 growth targets with automation and tech services, but faces margin risks from macro and competitive headwinds.
Omnicell ( OMCL ) Up 27% Since Last Earnings Report: Can It Continue?
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Advance Auto Parts Posts Upbeat Results, Joins Domo, LiveRamp, Urban Outfitters And Other Big Stocks Moving Higher On Thursday - Advance Auto Parts ( NYSE:AAP ) , Cantor Equity Partners ( NASDAQ:CEP )
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Thursday. Shares of Advance Auto Parts, Inc. AAP rose sharply during Thursday's session following better-than-expected first-quarter financial results.
Omnicell's New Perioperative Clinic Setting Products May Boost Stock
OMCL unveils new offerings for the perioperative and clinic setting.
This PVH Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Ameren ( NYSE:AEE ) , Establishment Labs Hldgs ( NASDAQ:ESTA )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Needham analyst Mike Matson upgraded the rating for Establishment Labs Holdings Inc.
Omnicell Q1 Earnings & Revenues Beat, '25 EPS View Down, Stock Up
OMCL posts better-than-expected top and bottom-line results for the first quarter of 2025.
Omnicell ( OMCL ) Beats Q1 Earnings and Revenue Estimates
Omnicell (OMCL) delivered earnings and revenue surprises of 62.50% and 4.24%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Can Sustained Product Demand Drive HIMS Stock Before Q1 Earnings?
The continued solid uptake of Hims & Hers offerings and expanding subscriber base are likely to have driven the company's performance in the first quarter of 2025.
Zacks Industry Outlook Highlights Veeva Systems, Hims & Hers Health and Butterfly Network
Veeva Systems, Hims & Hers Health and Butterfly Network are part of the Zacks Industry Outlook article.
Is it Apt to Retain Omnicell Stock in Your Portfolio Now?
OMCL stays on investors' radar due to the strong performance of the SaaS and Expert Services portfolio.
3 Medical Info Systems Stocks to Ride the AI Wave in Trump Tariff Era
Zacks Medical Info Systems industry stocks like VEEV, HIMS and BFLY are expected to gain from the Stargate Project and provide relief amid tariff tension.
New Product Launches Benefit GMED Stock Amid Macro Issues
Globus Medical currently awaits a strong cadence of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.
Omnicell Gains 41.6% in a Year: What's Driving the Stock?
OMCL's shares rise on the back of its XT Amplify program gaining market acceptance with its offerings. However, the unfavorable macroeconomic scenario is concerning.
Is it Apt to Retain Omnicell Stock in Your Portfolio Now?
OMCL stays on investors' radar due to its impressive long-term growth initiative.
Omnicell ( OMCL ) Upgraded to Buy: What Does It Mean for the Stock?
Omnicell (OMCL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ILMN Stock Might Rise From Collaboration With Broad Clinical Labs
Illumina Collaborates with Broad Clinical Labs to set the standard for scalable single-cell research and accelerate discovery in areas such as disease modeling and drug development.
Expanding Diabetes Business Supports ABT Stock, FX Issues Stay
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
BIO Stock Might Rise Following the Offer to Acquire Stilla
Bio-Rad offers to acquire all equity interests of Stilla Technology. The acquisition is expected to complement Bio-Rad's existing digital PCR portfolio.
ZBH Stock Hurt by Margin Concerns and Difficult Solvency
Zimmer Biomet is suffering due to macroeconomic uncertainties, pricing pressure and unfavorable currency fluctuations.
ALGN Stock Gains on the Launch of Invisalign Palatal Expander in Turkey
Align Technology commercially launches its Invisalign Palatal Expander System in Turkey after approval from TMMDA.
EMEA Expansion to Support BSX Stock Amid Fierce Competition
Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.
Wall Street Analysts Think Omnicell ( OMCL ) Could Surge 29.03%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 29% in Omnicell (OMCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
MYGN Stock Might Rise on Collaboration With CancerCARE
Myriad Genetics entered into an agreement with CancerCARE for Life to provide individuals within the latter's network with access to the MyRisk Hereditary Cancer Test.
Omnicell Q4 Earnings & Revenues Beat, Stock Up, Gross Margin Rises
OMCL returns to year-over-year revenue growth in the fourth quarter of 2024.
Omnicell ( OMCL ) Tops Q4 Earnings and Revenue Estimates
Omnicell (OMCL) delivered earnings and revenue surprises of 5.26% and 3.35%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
STXS Stock Gains Following the First Order for its GenesisX
Stereotaxis receives its first order for the next-generation robotic system, GenesisX. The company expects a full commercial launch in the coming months.
Inspire Medical Systems ( INSP ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Inspire (INSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Omnicell Stock a Solid Pick for Your Portfolio Right Now?
OMCL stays on investors' radar due to the strong performance of the Advanced Services portfolio.
Omnicell ( OMCL ) Reports Next Week: Wall Street Expects Earnings Growth
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Add PODD Stock to Your Portfolio Now
Insulet stays on investors' radar owing to its solid progress with Omnipod 5 and strong solvency position.
CLPT Stock Gains on FDA Clearance for Navigation Software Version 3.0
ClearPoint achieves FDA 510(k) clearance for its Navigation Software Version 3.0, designed to standardize cell and gene therapy delivery in the United States.
Reasons to Retain ABT Stock in Your Portfolio Now
Investors feel optimistic about Abbott's robust strength in the Core Diagnostics business. Yet, unfavorable forex impacts are concerning.
Expanding EPD Business Supports ABT Stock Amid Macro Issues
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
MYGN Stock Gains Following the Launch of Know More Sooner
Myriad Genetics launches an online prenatal genetic testing resource, the Know More Sooner website, to provide comprehensive information about reproductive and prenatal genetic testing.
Zacks Industry Outlook Enovis, Omnicell and Phreesia
Enovis, Omnicell and Phreesia have been highlighted in this Industry Outlook article.
3 Medical Info Systems Stocks to Buy as Stargate AI Drives Industry Prospects
Zacks Medical Info Systems industry stocks like Enovis, Omnicell and Phreesia are expected to gain from the GenAI wave.
The Zacks Analyst Blog Doximity, Omnicell, Embecta, Cencora and EDOC
Doximity, Omnicell, Embecta, Cencora and EDOC are included in this Analyst Blog.
4 MedTech Stocks Poised to Thrive Under Second Trump Presidency
Four MedTech stocks that are set to benefit from Trump 2.0 are DOCS, OMCL, EMBC and COR.
Emerging Market Expansion Supports ZBH Stock Amid Macro Issues
Zimmer Biomet is witnessing strong market share gains within reconstructive Knees and Hips in key geographies despite macroeconomic challenges.
